Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | DRD5 | P21918 | 1/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25438091 | 0.84 | KDM1A (0.43) | KDM1AHTR2CHTR2AHTR2BADRA2A | |
| SCHEMBL20232227 | 0.82 | KDM1A (0.44) | KDM1AHTR2CHTR2AHTR2BADRA2A | |
| SCHEMBL9818362 | 0.79 | KDM1A (0.43) | KDM1AHTR2CHTR2AHTR2BADRA2A | |
| SCHEMBL5305884 | 0.79 | ADRA2A (0.48) | HTR2CHTR2AHTR2BADRA2ADRD2 | |
| SCHEMBL1222499 | 0.78 | KDM1A (0.45) | KDM1AHTR2CHTR2AHTR2BADRA2A | |
| SCHEMBL19453895 | 0.78 | KDM1A (0.42) | KDM1AHTR2CHTR2AHTR2BADRA2A | |
| SCHEMBL29051650 | 0.78 | HTR2C (0.53) | KDM1AHTR2CHTR2AHTR2BADRA2A | |
| SCHEMBL12549679 | 0.77 | PARP10 (0.42) | HTR2CHTR2AADRA2A | |
| SCHEMBL16694747 | 0.77 | KDM1A (0.41) | KDM1AHTR2CHTR2AHTR2BADRA2A | |
| SCHEMBL19439341 | 0.77 | KDM1A (0.41) | KDM1AHTR2CHTR2AHTR2BADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-11084824-B2 | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-08-10 | — | — | US | disclosed |
| US-20200199129-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084824-B2 | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient | BTK, SYK, LCK | KDM1A 1031/4885HTR2C 3409/4885HTR2A 3879/4885 |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | KDM1A 1016/4885HTR2C 1304/4885HTR2A 1588/4885 |
| US-20200199129-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | BTK, SYK, LCK | KDM1A 1031/4885HTR2C 3409/4885HTR2A 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.